A more cautious viewpoint is provided by RCTs, which reveal that resveratrol did not significantly reduce ALT and AST levels in individuals with NAFLD, casting doubt on the supplement’s ability to enhance liver health in clinical settings (86). Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.